Adagio Medical Holdings, Inc Common Stock (ADGM) is a publicly traded Healthcare sector company. As of May 21, 2026, ADGM trades at $0.85 with a market cap of $19.62M and a P/E ratio of -0.58. ADGM moved +0.00% today. Year to date, ADGM is -18.08%; over the trailing twelve months it is -28.49%. Its 52-week range spans $0.63 to $4.20. Analyst consensus is buy with an average price target of $3.50. Rallies surfaces ADGM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Adagio Medical ULTC Feasibility Study Shows 92.9% Non-Inducibility and No Major AEs: Adagio Medical’s ULTC feasibility study of 20 ventricular tachycardia patients at four U.S. centers reported no major adverse events at 7 or 30 days and achieved 92.9% arrhythmia non-inducibility. At 24 weeks, 72% reduced or stopped antiarrhythmics and 83.3% remained free of ICD shocks.
| Metric | Value |
|---|---|
| Price | $0.85 |
| Market Cap | $19.62M |
| P/E Ratio | -0.58 |
| EPS | $-1.51 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.20 |
| 52-Week Low | $0.63 |
| Volume | 54 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-25.08M |
| Gross Margin | 0.00% |
2 analysts cover ADGM: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.50.